Harmony BiosciencesHRMY
About: Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Employees: 246
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
55% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 22
6% more funds holding
Funds holding: 204 [Q1] → 216 (+12) [Q2]
3% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 73
0.79% more ownership
Funds ownership: 87.53% [Q1] → 88.32% (+0.79%) [Q2]
9% less capital invested
Capital invested by funds: $1.67B [Q1] → $1.51B (-$155M) [Q2]
17% less funds holding in top 10
Funds holding in top 10: 6 [Q1] → 5 (-1) [Q2]
47% less call options, than puts
Call options by funds: $1.47M | Put options by funds: $2.78M
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Raymond James Danielle Brill 82% 1-year accuracy 14 / 17 met price target | 14%upside $40 | Outperform Reinstated | 10 Oct 2024 |
Mizuho Graig Suvannavejh 59% 1-year accuracy 17 / 29 met price target | 48%upside $52 | Outperform Maintained | 10 Oct 2024 |
Needham Ami Fadia 52% 1-year accuracy 26 / 50 met price target | 48%upside $52 | Buy Reiterated | 2 Oct 2024 |
Needham Ami Fadia 52% 1-year accuracy 26 / 50 met price target | 48%upside $52 | Buy Reiterated | 24 Sept 2024 |
Needham Ami Fadia 52% 1-year accuracy 26 / 50 met price target | 48%upside $52 | Buy Reiterated | 12 Sept 2024 |
Financial journalist opinion
Based on 25 articles about HRMY published over the past 30 days
